ERBB2 and breast carcinoma: The prognostic effect of HER2 status was evaluated and incorporated in the PREDICT tool for the first time in October 2011, based on data from the Breast Cancer Association Consortium (BCAC)6 consisting in 10,179 cases not exposed to anti-HER2 treatment (Supplementary Table 1).